Breast Cancer Clinical Trials in San Francisco, California
24 recruitingSan Francisco, California
Showing 1–20 of 24 trials
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+6 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
Breast CancerDepression
NRG Oncology402 enrolled277 locationsNCT06748222
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Not Applicable
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 1Phase 2
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Breast CancerSolid Tumors, Adult
Eli Lilly and Company720 enrolled67 locationsNCT05768139
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 2
ATEMPT 2.0: Adjuvant T-DM1 vs TH
Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute500 enrolled52 locationsNCT04893109
Recruiting
Phase 1Phase 2
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Breast CancerProstate Cancer Castration-resistant Prostate CancerColo-rectal Cancer+2 more
MBrace Therapeutics150 enrolled7 locationsNCT07145255
Recruiting
Phase 1
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Not Applicable
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
Breast CancerBreast Cancer Female
Breast Cancer Trials, Australia and New Zealand1,400 enrolled9 locationsNCT06445738
Recruiting
Not Applicable
Patient Care Outreach, Navigation, Technology and Support 2.0
Breast CancerCardiovascular Diseases
University of California, San Francisco260 enrolled2 locationsNCT06648278
Recruiting
Phase 1Phase 2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Breast CancerMetastatic Breast Cancer
Stemline Therapeutics, Inc.435 enrolled118 locationsNCT05563220
Recruiting
Phase 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
MOMA Therapeutics220 enrolled18 locationsNCT06545942
Recruiting
Not Applicable
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Breast CancerBreast Cancer ScreeningBreast Carcinoma in Situ
University of California, San Francisco100,000 enrolled11 locationsNCT02620852
Recruiting
Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Breast Cancer
Agendia30,000 enrolled134 locationsNCT03053193
Recruiting
Phase 2
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Breast Cancer
Dana-Farber Cancer Institute40 enrolled7 locationsNCT04434040